Nachrichten zur Abbvie Inc. Aktie

AbbVie Wins FDA Nod for New Parkinsons Disease Drug Juvmo

ABBV wins FDA approval for Juvmo, expanding its Parkinsons portfolio with a once-daily oral treatment and potential $5B-plus PD opportunity.…

AbbVie: Nach Humira zurück auf Wachstumskurs – neue Milliardenpotenziale und KGV 16,4

AbbVie ist ein führender Biopharma-Konzern und ersetzt den Humira-Rückgang zunehmend mit neuen Wachstumstreibern aus Immunologie, Neurologie und Onkologie. Skyrizi…

The Zacks Analyst Blog Highlights Alphabet, Mastercard, AbbVie, Perma-Pipe and ImmuCell

GOOGL, MA and ABBV headline todays research, with AI-led growth, electronic payments and strong drug portfolios shaping their outlooks.…

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie bets on pipeline diversification amid patent cliffs, while J&Js higher profitability masks litigation risks, a choice between growth ambition…

AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and…

Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut

ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran…

AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?

AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly…

Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?

AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.…

AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?

These companies are committed to rewarding shareholders.…

AbbVie’s Rinvoq wins EU approval for pediatric arthritis

AbbVie’s Rinvoq wins EU approval for pediatric arthritis…

AbbVies Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?

AbbVies market-beating days dont seem to be over yet.…

Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside

Citadel, Ken Griffins hedge fund, materially increased its stake in AbbVie; heres why you may want to follow that lead.…

AbbVie (ABBV) Advances While Market Declines: Some Information for Investors

The latest trading day saw AbbVie (ABBV) settling at $261.7, representing a +1.78% change from its previous close.…

AbbVies Atogepant Meets Goal in Late-Stage Menstrual Migraine Study

ABBVs atogepant delivers positive LUNA data in menstrual migraine, potentially expanding its migraine franchise and addressing an unmet need.…

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

AbbVies diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.…

AbbVies Immunology Franchise: From Skyrizi & Rinvoq to Whats Next

ABBVs Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.…

ADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie

…

ROUNDUP: Botox und Co. - Minimalinvasive Eingriffe immer gefragter

BERLIN (dpa-AFX) - Immer mehr Menschen lassen minimalinvasive Eingriffe beim Schönheitschirurgen durchführen. Zu minimalinvasiven Eingriffen gehören…

dpa-AFX ProFeed